Biblio
Correction: TET2 deficiency promotes MDS-associated leukemogenesis. Blood Cancer J. 2023;13(1):174.
Disruption of dNTPs Homeostasis by Ribonucleotide Reductase Hyperactivation Overcomes AML Differentiation Blockade. Blood. 2022.
HDAC4 inhibition disrupts TET2 function in high-risk MDS and AML. Aging (Albany NY). 2020;12.